With Plans For Public Offerings, Emcure, Intas Set To Join Big League Of Indian Pharma
This article was originally published in PharmAsia News
Experts believe Emcure and Intas may be able to withstand the vagaries of India’s choppy financial market, having developed strong pedigrees of products and consistently growing their businesses.
You may also be interested in...
With Emerging Markets On Radar, AstraZeneca Close To Teaming Up With India's Intas For Sourcing Sterile And Oncology Drugs
MUMBAI - AstraZeneca is days away from signing an agreement with India's Intas Pharmaceuticals for supplies of a large number of generic sterile and oncology products to be sold in emerging markets. The deal will likely cover as many as 45 products to be sold in nine markets, with the scope for expanding the range of products further
After Launching First Pegylated GCSF, Intas Biopharma Examines Technology For Pegylated Erythropoietin
MUMBAI - Ahmedabad, India-based biotech firm Intas Biopharma is looking at commencing research on a generic form of pegylated erythropoietin
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.